Vivek admitted that neither of his parents were citizens at the time of his birth in a September 2023 interview with NBC's Dasha Burns. That same month at a Republican Presidential Primary Debate he said he would end birthright citizenship if he were elected.

As CEO of Roivant Sciences, Vivek implemented a DEI policy called Roivant Social Ventures in 2020 with the goal to foster "DEI opportunities for future leaders in biopharma and biotech." This initiative helped him get investment from investors like BlackRock.

In 2011 Vivek accepted a $90,000 award from the Paul & Daisy Soros Fellowship for New Americans, which was founded by Daisy and Paul Soros, the late older brother of George Soros. He claimed he needed the money to afford Law School but his tax returns show he was already a multi millionaire at that time.

Despite saying that he would "gut" the H1-B lottery program, he himself used the H1-B visa to hire non-American workers for his companies for over half a decade.

Vivek's company Axovant Gene Therapies owned a drug called Intepirdine which failed to pass Phase 2 clinical trials. His solution was to redo the trials, but this time they were conducted by his mother Geetha. Incredibly, the trials demonstrated significant improvements from the last ones, enough to move on to Phase 3. At this point, he took his company public for a $315 million IPO in 2015, the largest of any biotech company in history. When the drug moved onto phase 3 trials that were not conducted by his mother, they failed, and the company lost 75% of its value in a single day. Luckily for Vivek, however, he had already sold tens of millions of dollars in his shares of the company, and so the losses didn't hurt his wallet.

Vivek has openly criticized Trump numerous times, including calling him "downright abhorrent" and saying we need to "forget about him" after his "egregious behavior" after January 6th.